Arrowstreet Capital’s Atara Biotherapeutics ATRA Stock Holding History

Arrowstreet Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,864	Closed	-$2.73M	–	1323
2022 Q3	$2.73M	Buy	28,864 +22,515	+355%	+$2.53M	﹤0.01%	793
2022 Q2	$1.24M	Buy	6,349 +4,637	+271%	+$757K	﹤0.01%	889
2022 Q1	$398K	Buy	+1,712	New	+$545K	﹤0.01%	1053
2021 Q1	–	Sell	-3,485	Closed	-$1.71M	–	2232
2020 Q4	$1.71M	Buy	3,485 +1,765	+103%	+$815K	﹤0.01%	1659
2020 Q3	$557K	Buy	+1,720	New	+$586K	﹤0.01%	1988

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital's ATRA Position: Q4 2022 in Review

Arrowstreet Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 28,864 shares — an estimated $2.73M sold.

Arrowstreet Capital first reported a position in ATRA in Q3 2020 and held it in 5 quarters. The position peaked at $2.73M in Q3 2022. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

Arrowstreet Capital reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Arrowstreet Capital sold 28,864 Atara Biotherapeutics shares in Q4 2022, an estimated $2.73M.
Arrowstreet Capital first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 5 quarters.
Arrowstreet Capital's Atara Biotherapeutics position peaked at $2.73M in Q3 2022.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Arrowstreet Capital's 13F filing for Q4 2022, filed 14 Feb 2023.